Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- OPINION／How Marketing Moves in Mysterious Ways
December 7, 2009
- Daiichi Sankyo Wins Levofloxacin Patent Lawsuit in the UK
November 30, 2009
- Liraglutide Prevents Weight Gain in Japanese Patients
November 30, 2009
- Greater Efforts Needed to Foster Ventures: Mr Kawakami
November 30, 2009
- Record Productivity Achieved for CHO Cells with BI-HEX Platform: BI
November 30, 2009
- Rasilez's Benefits for Hypertension Recognized by Updated ESH GL: Novartis
November 30, 2009
- Over 60% of Consumers Desire Vaccination against New-Type Flu but with Domestic Vaccines
November 30, 2009
- Miraka HD: Operating Profits Up 48% Driven by Flu-Related Products
November 30, 2009
- Megapharmas Will Flee from Japan Unless Gov't Promotes Industry: Mr Dunoyer
November 30, 2009
- Pfizer Embarks on Generics Business in Japan
November 30, 2009
- Taisho Acquires BMS's OTC Drugs Business in Asia, Pacific
November 30, 2009
- Combined Sales of 21 JPMA Member Companies Up 1.6%
November 30, 2009
- 68% of Prescriptions Permit Generic Substitution, But 88% of Them Not Filled with Generics: Survey
November 30, 2009
- Sato Pharm. Launches Switch OTC Version of Vidarabine
November 30, 2009
- Otsuka HD: Pharma Division Sales Total ¥357.5 Bil.
November 30, 2009
- Market for Generics to Expand to ¥447.9 Bil. in 2011: Fuji Keizai
November 30, 2009
- Kobayashi Pharm.: Sales Up 4.9% due to Influenza Pandemic
November 30, 2009
- Kaken Licenses bFGF to Olympus in Europe, North America
November 30, 2009
- Generics Dispensing Rate Has No Clear Effects on Pharmacies' Business
November 30, 2009
- Adverse Reactions Reported due to GSK's Flu Vaccine
November 30, 2009
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…